TKI Cancer Treatment Resistance Linked to Common Germline Variant in East Asian Populations | GenomeWeb

By Andrea Anderson

NEW YORK (GenomeWeb News) – A Singapore-led team has identified a germline polymorphism that appears to account for reduced drug response in some East Asian cancer patients treated with tyrosine kinase inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.